INTRODUCTION
Survival of extremely premature infants has improved over the past two decades due to advances in technology and treatment strategies. Neonatologists continue to experience difficulty with the management of patent ductus arteriosus (PDA) in this high-risk group of infants. PDA may be present in over 80% of extremely low birth weight infants with birth weights less than 1000 g.
1,2 Early administration of low-dose indomethacin to these infants to reduce the risk of severe intraventricular hemorrhage (IVH) is an accepted form of therapy. 1, 3 Early administration of low-dose indomethacin to these infants reduces the incidence of PDA, 1 -4 but it is unclear whether it reduces the need for surgical PDA ligation. The outcome of the extremely premature infants <27 weeks' gestational age who are at greatest risk for IVH, PDA, and other morbidities associated with extreme prematurity has not been specifically addressed. We hypothesized that early diagnosis and medical treatment of PDA with therapeutic doses of indomethacin would be associated with a reduced need for later PDA ligation in a selected high-risk population. We conducted a retrospective chart review of infants <27 weeks' gestational age or <800 g birth weight born at our institution between 1995 and 2001. These infants are at the greatest risk of needing surgical ligation of a PDA and for developing severe IVH. We compared infants treated with indomethacin within the first 48 hours of life with those treated for a clinically symptomatic PDA after 48 hours. We compare the need for surgical ligation of PDA, mortality and morbidity rates between groups.
METHODS
The retrospective chart review included 65 infants <27 completed weeks' gestation or with a birth weight <800 g who were born at our institution between January 1995 and January 2001 ( Table 1) . The Institutional Review Board approved the chart review at Boston Medical Center. Infants were divided into an early treatment group (ETG) of infants who received their first dose of indomethacin within the first 48 hours of life, and a standard treatment group (STG) of infants, managed expectantly, receiving their first dose after 48 hours of life for a clinically symptomatic PDA. Indomethacin was initially administered to infants in the ETG for IVH prophylaxis using indomethacin 0.1 mg/kg per dose every 24 hours. 1, 3, 5 The indomethacin dose was increased when a hemodynamically significant Survival of extremely premature infants ( < 27 weeks' gestational age ) has improved over the past two decades. Indomethacin prophylaxis was used in these infants, who have the highest mortality and morbidity rates, to reduce the incidence of intraventricular hemorrhage and patent ductus arteriosus ( PDA ). Medical records of 65 extremely premature infants born at our institution between 1995 and 2001 were reviewed retrospectively to determine whether treatment of PDA with indomethacin in the first 48 hours of life reduces the need for PDA ligation or increases neonatal morbidity, when compared to treatment begun later. Thirty infants in the early treatment group ( ETG ) were treated during the first 48 hours after birth, and 32 infants in the standard treatment group ( STG ) were managed expectantly for PDA. Three infants died in the first hours of life and were eliminated from further analysis. ETG infants were 24.9 ± 1.1 ( mean ± SD ) weeks' gestation with a birth weight of 678 ± 143 g. STG infants were 25.3 ± 1.1 weeks ( NS ) and 730 ± 125 g ( NS ). Hemodynamically significant PDA was diagnosed or confirmed by echocardiography in 19 ETG patients and 17 STG patients. Of the patients with hemodynamically significant PDA, 1 ( 5% ) ETG patient and 6 ( 35% ) STG patients underwent surgical ligation ( p = 0.033 ). Necrotizing enterocolitis ( NEC ) with intestinal perforation was the most serious morbidity and occurred in 20% of infants in the ETG, but in no STG infant ( p = 0.011 ). Four of the six infants in the ETG with NEC and intestinal perforation died. The overall mortality rate for all infants studied was 28%. We conclude that in extremely premature infants, use of indomethacin during the first 48 hours of life was associated with a reduced need for PDA ligation, but an increased risk of NEC with intestinal perforation. Journal of Perinatology (2002) 22, 535 -540 doi:10.1038/sj.jp.7210795
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PDA was documented by echocardiography, if there were no contraindications. Indomethacin 0.2 mg/kg per dose, followed by 0.1 to 0.2 mg/kg per dose every 12 hours for two to three doses was administered for a hemodynamically significant PDA. 5 All infants treated for a clinically significant PDA after 48 hours received indomethacin 0.2 mg/kg per dose every 12 hours for one to three doses. Subsequent doses of indomethacin for a persistent PDA were at the discretion of the attending neonatologist and pediatric cardiologist.
In the ETG, each infant was diagnosed as having a hemodynamically significant PDA by echocardiography before changing indomethacin dosing (Table 2 ). In the STG, a clinically significant PDA was recognized by a characteristic heart murmur, associated physical signs, and persistent need for ventilator support. All except one of the infants in the STG had a significant PDA diagnosed by echocardiography before institution of indomethacin therapy. Echocardiography confirmed the clinical assessment in each infant treated for a clinically significant PDA. All infants in the ETG were assessed by echocardiography during their hospitalization. Twenty-five of the 30 infants in the ETG were evaluated by echocardiography before 48 hours of life. Twenty-nine of the 32 patients in the STG were assessed by echocardiography during their hospitalization for clinical indications. Complete two-dimensional echocardiography and Doppler assessment was performed during the initial evaluation to rule out structural congenital heart disease using a Sonos 1500 or 5500 (Hewlett Packard, Andover, MA) with a 7.5-or 12-MHz transducer, respectively. PDA was considered hemodynamically significant by echocardiography when there was continuous left to right flow through the ductus arteriosus, holodiastolic retrograde blood flow in the descending thoracic aortic, and left atrial enlargement. 4, 6 Serial echocardiograms were performed to assess persistent ductal patency. All intravenous indomethacin doses were administered over 30 minutes. All patients were maintained NPO and maintained on parenteral fluids during the period when indomethacin was administered. The decision for PDA ligation was at the discretion of the attending neonatologist and pediatric cardiologist. Criteria for PDA ligation included a hemodynamically significant PDA by echocardiography, ventilator dependence, and failure of indomethacin to successfully manage the PDA or a contraindication to the use of indomethacin. 5 Potential contributors to clinically symptomatic PDA were assessed. Surfactant (Survanta, Ross Pharmaceuticals) usage 5 was tabulated. Surfactant was administered to 93% of ETG infants and 91% of STG infants. Maximum parenteral fluid infusion rates and serum sodium concentration during the first 4 days of life were tabulated to determine whether there were differences in fluid management or hydration of infants in the two groups. The age at initiation of high-dose systemic dexamethasone was tabulated, as high-dose steroids may contribute to the development of necrotizing enterocolitis (NEC) and intestinal perforation and decrease the incidence of PDA.
The duration of respiratory support and oxygen therapy was analyzed to determine whether there was a difference in the rate of bronchopulmonary dysplasia (BPD) between groups. BPD was defined as need for supplemental oxygen beyond 36 weeks postconceptual age. Six ETG and seven STG infants were discharged home or transferred to other institutions while still receiving supplemental oxygen. All these infants were greater than 36 weeks postconceptual age at discharge or transfer. The duration of oxygen therapy for these babies was calculated to the discharge or transfer date.
Cranial ultrasounds were routinely performed during the first 3 days and at 1, 2, and 4 weeks of life to determine whether there were differences in the severity of IVH between groups. IVH severity was classified into four grades. 7 The frequency of NEC was assessed to determine if this morbidity of prematurity was more common in the ETG or STG infants ( Table 3 ). Diagnosis of NEC was made by the attending neonatologist and did not require radiographic documentation of pneumatosis intestinale. NEC was defined clinically by (1) the presence of dilated or fixed loops of bowel on an abdominal radiograph, persistent gasless abdomen, guiac positive stools, significant gastric aspirates and 10 day course of intravenous antibiotics or (2) the presence of pneumatosis intestinalis, portal gas, or free air on abdominal radiograph. Surgical laparotomy or autopsy confirmed the diagnosis of NEC with intestinal perforation in all The frequency of retinopathy of prematurity (ROP) was assessed to determine whether early use of indomethacin reduced the severity of ROP in these high-risk infants. ROP was diagnosed by a pediatric ophthalmologist experienced in the diagnosis and management of ROP. Severity of ROP was reported as the stage of ROP. 8, 9 Threshold ROP treated with cryotherapy or laser was numerically designated 3.5, unless stage 4 or 5 was documented.
Statistical analysis was performed using a two-tailed Student t-test for continuous variables and chi-square test for discrete variables. Continuous variables were reported as mean±SD. Discrete variables were presented as number and percent, followed by relative risk (RR) and 95% confidence intervals (CI). Chi-square test was calculated using EpiInfo 2000 (NIH). Mantel-Haenszel test was used for most comparisons. Fisher two-tailed exact test was applied when appropriate. Significant differences were accepted at the p<0.05 level.
RESULTS
Sixty-five infants <27 weeks' gestation or <800 g birth weight were born during the review period; 30 received indomethacin in the first 48 hours (ETG) and 32 were managed expectantly for a symptomatic PDA (STG). Three infants died within the first hours of life and were eliminated from further analysis. Infants in the ETG were 24.9±1.1 weeks' (mean±SD) gestational age and had a birth weight of 678±143 g. Infants in the STG were similar, with a gestational age of 25.3±1.1 weeks' gestation (NS) and a birth weight of 730±125 g (NS). Antenatal steroids (at least one dose) had been administered to the mothers of all but one infant in each group. Apgar scores at 1 and 5 minutes were not significantly different between the two groups. All infants were mechanically ventilated. Infants in the ETG received assisted ventilation (mechanical ventilation or continuous positive airway pressure) for 53±27 days, similar to 49±18 days in the STG ( p=0.564) ( Table 4) . BPD requiring oxygen therapy beyond 36 weeks postconceptual age occurred in 11 (55%) surviving infants in the ETG and 15 (58%) surviving infants in the STG (RR 0.95, CI 0.57 to 1.60, p=0.857).
ETG infants received their first dose of indomethacin at 1.2±0.7 days whereas infants in the STG received their first dose at 6.4±4.7 days ( p<0.001). In the ETG, 19 infants (63%) had a significant PDA by echocardiography and received therapeutic doses of indomethacin; 15 infants (47%) in the STG were treated with therapeutic doses of indomethacin (RR 1.16, CI 0.77 to 1.74, p=0.490). Infants in both groups received a similar number of indomethacin doses: 3.6±2.1 doses in the ETG and 4.1±2.7 doses in the STG ( p=0.474). Infants in the ETG (n=30) had their first echocardiographic assessment at 2.1±2.3 days, whereas in the STG (n=29) echocardiographic assessment was at 9.8±21.1 days ( p=0.052). Of the 15 patients in the STG treated with indomethacin for a hemodynamically significant PDA, echocardiographic evaluation was performed at 4.8±3.1 days.
The rate of PDA ligation was significantly lower in the ETG compared with the STG. One of 19 (5%) infants with PDA in the ETG and 6 of 17 (35%) infants with PDA in the STG underwent surgical ligation (RR 0.15, CI 0.02 to 1.08, p=0.033 with Fisher correction). One infant in the ETG required surgical PDA ligation at 30 days, whereas PDA ligation occurred at 18±9 days in the STG.
Surfactant usage was similar in the two groups and was administered to all but two ETG infants and all but three STG infants. ETG infants received 2.2±0.9 doses of surfactant and STG infants received 1.8±0.9 doses (NS).
Maximal parenteral fluid administration rate in the first 3 days was assessed to determine whether there were differences in initial fluid management between groups. Initial parenteral fluid administration was 100 to 120 ml/kg per day, and increased in response to hypernatremic dehydration and hypotension. Maximal total parenteral fluid administration rate in the ETG was 266±111 Four ETG infants with NEC and perforation received more than three doses of indomethacin. Four ETG infants with NEC and perforation died, and these infants received 4±1 doses of indomethacin (range three to five doses). Eight ETG and 4 STG infants received more than three doses of indomethacin. None of the STG infants who received more than three doses of indomethacin died.
We assessed the age of initiation of high-dose dexamethasone to determine whether this may have contributed to the development of NEC with intestinal perforation. Dexamethasone was first administered to 22 (73%) ETG infants at 11.0±5.4 days and 17 (53%) STG infants (RR 1.30, CI 0.88 to 1.97, p=0.173) at 16.2±11.0 days ( p=0.70). Three of the ETG infants with NEC and intestinal perforation received their first dose of systemic dexamethasone at 9.8±9.4 days, before the clinical recognition of NEC with intestinal perforation; all of whom died. Three ETG infants and 1 STG infant received indomethacin and steroids concomitantly. None of these infants developed intestinal perforation or died.
Other morbidities common in extremely premature infants were not significantly different. ROP was diagnosed in 20 (85%) of the infants surviving in the ETG and 24 (92%) of infants surviving in the STG (RR 0.87, 0.38 to 1.11, p=0.380 with Fisher correction). Mean ROP stage was 1.95±1.15 in the ETG and 2.46±1.09 in the STG ( p=0.129). Threshold ROP developed in 1 (6%) ETG and 5 (21%) STG infants (RR 0.30, CI 0.04 to 2.33, p=0.373 with Fisher correction). Grade 3 to 4 IVH was noted in 5 (17%) ETG, and 10 (31%) STG infants (RR 0.52, 0.13 to 2.07, p=0.460). Periventricular leukomalacia developed in 5 (17%) ETG and 5 (16%) STG infants (RR 1.23, CI 0.40 to 3.80, p=0.740). BPD (oxygen requirement after more than 36 weeks postconceptional age) rate was similar in the two groups. Eleven infants (55% of survivors) in the ETG and 15 infants (58% of survivors) in the STG developed BPD (RR 0.95, 0.57 to 1.60, p=0.857) . The length of NICU stay for ETG survivors was 111±26 days, similar to 114±22 days in the STG ( p=0.618). There were 10 deaths (33%) in the ETG and 6 deaths (19%) in the STG (RR 1.78, 0.74 to 4.29, p=0.191). Death occurred at 11±10 days in the ETG infants and at 22±20 days ( p=0.178) in the STG infants. When the three early deaths (excluded from the above analysis) were included, overall mortality for the entire cohort was 28%.
DISCUSSION
The primary new finding of this study is that NEC with intestinal perforation occurred in 20% of ETG extremely premature infants ( <27 weeks or <800 g birth weight) treated with indomethacin in the first 48 hours of life but in none of the STG infants treated for a symptomatic PDA after 48 hours of life. In contrast, the overall incidence of NEC in ETG and STG infants was similar (33% and 28%, respectively). Thus, 60% of the infants in the ETG who developed NEC, also developed intestinal perforation. The extremely premature infants in the ETG were initially treated with indomethacin for IVH prophylaxis. The dose of indomethacin was increased for management of a significant PDA diagnosed by echocardiography on the second day of life. Of the six infants in the ETG who developed NEC with intestinal perforation, four died from NEC or the complications of NEC. Barton and colleagues 10 evaluated a similar population and report NEC in 30% of the 10 infants who received low-dose indomethacin (0.1 mg/kg per dose) within the first 2 days of life. Although the incidence of NEC is similar to our study, none of their infants developed intestinal perforation. The intestinal perforation rate in our patients with NEC (60%) is nearly double that reported by Grosfeld et al. 11 who report NEC in 35% of 224 extremely premature infants (26.9±0.27 weeks' gestation) treated with indomethacin between 3 and 7 days of life. Intestinal perforation occurs in 38% of these infants, with 56% mortality. NEC with intestinal perforation in our ETG is higher than previously reported.
Reports of the association between indomethacin and NEC are inconsistent. 1 -4,10 -12 Our study differs from prior reports that do not show a significant association between indomethacin and NEC with perforation, in that we focus on a select population of extremely premature infants. These infants are at the greatest risk for PDA, NEC, and IVH. We speculate that prolonged decreases in mesenteric blood flow velocity induced by therapeutic doses of indomethacin 12 may be responsible for the development of NEC and intestinal perforation, but a causal link is not clearly established. In addition, nearly all of our infants, both in the ETG and STG, were exposed to antenatal steroids shortly before delivery. Whereas antenatal steroids are generally considered to reduce the risk of NEC, 13 a recent report suggests an increased risk for NEC.
14 Three infants with NEC and intestinal perforation received early high-dose postnatal steroids ( <2 weeks of life), which have been reported to be associated with focal small intestinal perforation without NEC. 15 -18 Other investigators do not note an increased incidence of NEC when 20 report NEC developed in 11% of premature infants <1000 g birth weight who received low-dose indomethacin (0.1 mg/kg per dose every 24 hours) and in 10% of the infants who received placebo. Half of the infants with NEC in each group developed intestinal perforation.
We speculate that the combination of early therapeutic doses of indomethacin for PDA and antenatal steroid administration in our infants may have predisposed them to develop NEC with intestinal perforation at a rate much higher than previously reported. 11 The mechanism of the interaction may arise from the combined effects of indomethacin and steroids on the inhibition of prostaglandin synthesis. 18, 21 This interaction on the mesenteric vasculature, however, may be specific to indomethacin, which appears to have a direct vasoconstrictor effect not seen with ibuprofen, another nonselective cyclooxygenase inhibitor. 12 The contribution of postnatal high-dose systemic steroid administration is difficult to assess, as we have discontinued this practice. An alternative explanation for the high incidence of NEC with perforation in the ETG is that the groups may not be comparable. The ETG infants may have exhibited signs and symptoms of PDA earlier, prompting earlier indomethacin use than in the STG, as only 16 (43%) of infants in the STG received indomethacin. However, based on these available data from infants at a single institution, the most consistent risk factor for NEC with intestinal perforation was the administration of indomethacin within the first 48 hours of life. Whereas our report is a retrospective study of extremely premature infants, it seems prudent to avoid administration of therapeutic doses of indomethacin to this population for management of PDA in the first 48 hours of life and to be aware of the interaction between indomethacin and steroids on the mesenteric vasculature. 18 We believe that early administration of indomethacin to this high-risk subgroup of extremely premature infants is associated with an increased incidence of NEC with intestinal perforation, which is associated with an increased mortality rate.
11
A primary goal of this study is to determine whether early administration of therapeutic doses of indomethacin within the first 48 hours of life to extremely premature infants with PDA would reduce the need for later PDA ligation. The PDA ligation rate in the ETG is 5% and in the STG is 35% of infants diagnosed with a hemodynamically significant PDA by echocardiography. Whereas others report a reduced incidence of PDA with early indomethacin therapy, the need for surgical ligation is not consistently reduced. 2, 4, 19 We speculate that the combination of perinatally administered steroids and early indomethacin administration may increase the force of periductal smooth muscle contraction, increasing the PDA closure rate and reducing the need for subsequent surgical ligation. Increased periductal smooth muscle contraction with a combination of indomethacin and steroids have been demonstrated in a rat model of PDA. 22 Whereas our data suggest that early treatment with indomethacin may have reduced the need for surgical PDA ligation, the rate of NEC with intestinal perforation overshadows this potential beneficial effect. It may be that those factors responsible for a more forceful ductal constriction were also responsible for NEC with intestinal perforation.
A trend toward a lower incidence of threshold ROP requiring cryotherapy or laser treatment is noted in infants in the ETG. Indomethacin treatment of PDA is associated with a reduction in severe ROP in a large multicenter collaborative study. 23 Other studies do not note this effect. Indomethacin reduces oxygen-induced retinopathy in a mouse model of ROP 24 and may have a prostaglandin mediated vascular contribution. 25 Our study is too small to show a significant effect of early indomethacin administration on ROP. There may be other more specific vasoactive drugs found to prevent the development of severe ROP.
A trend toward a lower incidence of Grade 3 to 4 IVH in the ETG is apparent, although not significant. The effect of indomethacin on IVH incidence has been noted by others 1, 26 and is a recommended, 3 although inconsistently applied therapy. Given the potential benefits from prophylactic management of PDA in this very high-risk population, a drug with fewer side effects than indomethacin is needed. Early experience with intravenous lysine ibuprofen for the medical management of PDA suggests that ibuprofen is as effective as indomethacin with fewer side effects. 27 -30 Whether ibuprofen or another cyclooxygenase inhibitor will have the same efficacy as indomethacin in medically closing PDA, without the undesirable side effects, has yet to be determined. The potential severe adverse reactions to early therapeutic indomethacin administration to extremely premature infants, and the potential beneficial responses to early treatment, suggest some urgency in finding an alternative drug.
